OncoMatch/Clinical Trials/NCT07437898
Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
Is NCT07437898 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Adebrelimab and chemotherapy for esophageal squamous cell carcinoma.
Treatment: Adebrelimab · chemotherapy — This is a domestic exploratory, single-arm clinical study enrolling patients with histologically or cytologically confirmed locally advanced esophageal squamous cell carcinoma (ESCC), aiming to evaluate the efficacy and safety of neoadjuvant adebrelimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CT1B-CT2N+M0, CT3-CT4A ANY N M0 (clinical (cTNM))
Clinical stage: cT1b-cT2N+M0 or cT3-cT4a any N M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiotherapy
No prior anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, surgery, etc.
Cannot have received: chemotherapy
No prior anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, surgery, etc.
Cannot have received: surgery
No prior anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, surgery, etc.
Cannot have received: immunotherapy
Previous or ongoing receipt of any of the following therapies: Any radiotherapy, chemotherapy, immunotherapy, targeted therapy, or other antitumor therapy for malignancy
Cannot have received: targeted therapy
Previous or ongoing receipt of any of the following therapies: Any radiotherapy, chemotherapy, immunotherapy, targeted therapy, or other antitumor therapy for malignancy
Lab requirements
Blood counts
WBC ≥ 3.0×10⁹/L; ANC ≥ 1.0×10⁹/L; Platelet count ≥ 80×10⁹/L; Hemoglobin ≥ 90 g/L
Kidney function
Serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault)
Liver function
Total bilirubin ≤ 1.5×ULN; ALT ≤ 2.5×ULN; AST ≤ 2.5×ULN
Adequate organ function, as defined below: Hematologic parameters... Blood biochemistry... Coagulation function: INR ≤ 1.5×ULN; APTT ≤ 1.5×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07437898 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage CT1B-CT2N+M0 or CT3-CT4A ANY N M0 is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages